These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26586670)

  • 1. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
    Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What Is Breast in the Bone?
    Shemanko CS; Cong Y; Forsyth A
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
    Hachim IY; Shams A; Lebrun JJ; Ali S
    Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
    Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
    Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
    Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
    Gutzman JH; Miller KK; Schuler LA
    J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
    Lim JH; Kim TY; Kim WH; Park JW
    Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of prolactin and its receptor in human breast carcinoma.
    Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
    Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
    Kavarthapu R; Dufau ML
    Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
    Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
    Kavarthapu R; Dufau ML
    Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin receptor in breast cancer: marker for metastatic risk.
    Shemanko CS
    J Mol Endocrinol; 2016 Nov; 57(4):R153-R165. PubMed ID: 27658959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha
    Castillo LF; Rivero EM; Goffin V; Lüthy IA
    Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
    Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
    Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
    Standing D; Dandawate P; Anant S
    Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT; Chen NY; Franek KJ; Chen WY
    Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy.
    López-Ozuna VM; Hachim IY; Hachim MY; Lebrun JJ; Ali S
    Sci Rep; 2016 Aug; 6():30934. PubMed ID: 27480353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration.
    Li R; Yang Y; Lan H; Wang Y; Ge Z; Liu X; Zhou Y; Zhang W; Xian L; Yuan H
    Endocrinology; 2023 Nov; 164(12):. PubMed ID: 37934803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
    Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
    Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
    Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.